Fujifilm Biotech Breaks Ground on $1.6-Bn Expansion of Cell-Culture Mfg

Fujifilm Diosynth Biotechnologies, a contract biologics manufacturer, has broken ground on an expansion of its site in Hillerød, Denmark, to expand cell-culture biomanufacturing. The expansion is part of a $1.6-billion capital investment that the company had announced earlier this year (July 2022).

Fujifilm Diosynth acquired the Hillerød site from Biogen in 2019 for approximately $890 million. The expansion will increase the capacity of the current site by adding 8 x 20,000-L bioreactors and two downstream processing streams. When the expansion is completed, the site will offer a total of 20 x 20,000-L bioreactors for drug-substance production as well as drug-product and finished goods services.

The expansion is expected to be completed in the summer of 2026 and will create 450 jobs.

Source: Fujifilm Diosynth Biotechnologies